ImmunityBio Confirms Statistical Power in Pivotal Randomized BCG-Naïve NMIBC Trial to Detect Clinically Meaningful Differences Between ANKTIVA® Plus BCG Versu…

ImmunityBio, Inc. (NASDAQ: IBRX), a vertically integrated, commercial-stage immunotherapy company, today announced that based ...

ImmunityBio lead bladder cancer drug trial clears power check

ImmunityBio Inc. IBRX shares are down during Thursday’s premarket session. Year to date, the stock has jumped over 300%. The ...
Science Daily

New method improves survival analysis power in clinical and epidemiological studies

Innovative statistical method helps determine ideal threshold times in restricted mean survival time analyses. The restricted mean survival time (RMST) analysis technique was introduced in health care ...
ascopubs.org

Biomarkers in Oncology: Complexities in Biomarker-Driven Studies and Statistical Analysis

In oncology drug development, biomarker-driven studies are pivotal, enabling the selection of patient populations most likely to benefit from specific therapeutic interventions. These studies have ...